about
START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionCardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusInterferon-alpha, immune activation and immune dysfunction in treated HIV infectionMonocytes as regulators of inflammation and HIV-related comorbidities during cARTHIV infection and cardiovascular diseaseArterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?Distinct phenotype, longitudinal changes of numbers and cell-associated virus in blood dendritic cells in SIV-infected CD8-lymphocyte depleted macaquesFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVCardiovascular Complications of HIV Infection.Ageing and inflammation in patients with HIV infection.Cardiovascular Complications of HIV in Endemic Countries.Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda.Contrast-Enhanced Ultrasound: A Novel Noninvasive, Nonionizing Method for the Detection of Brown Adipose Tissue in Humans.Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infectionHIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammationReduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance PElevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis.Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by 82Rb PET/CT in HIV-Infected Patients.Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls.Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.Inflammation, Immune Activation, and Antiretroviral Therapy in HIVSwitch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsClinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recurrent same-site deep vein thrombosis by illuminating recently formed, neutrophil-rich thrombus.T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHSChronic HIV disease and activation of the coagulation systemSoluble CD163 is associated with shortened telomere length in HIV-infected patients.HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort.Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study.Increased coronary vessel wall thickness in HIV-infected young adults.Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?
P2860
Q26753830-85C07787-1BEB-4B89-BD23-14536D0BB859Q26777866-1EDC9C0B-429C-4732-A731-E67F0915A629Q26851535-4D7649CD-51B1-4A2D-8115-F8245A527060Q26861003-E5B8CAD2-9FE7-4E18-9584-DFA025A41082Q27006827-9B778BB0-4FF9-46E7-91DC-FA3D99262EA6Q27008915-A33D8C75-DCCF-4B8E-965B-CC0DE55D8A72Q27026486-F0378056-24CC-4318-ACA0-D2375E9C8EBDQ27311668-73E43668-FCAF-439F-8D91-1F444E99696DQ28079826-20766FA7-A90E-4258-8CA0-DCE3225F3CC5Q30235920-3FE5DA60-8B8C-4DF4-B157-4B4D2B995F98Q30244296-4BCE52AD-59E6-45D0-B78A-918C7B9C5688Q30244655-12D99C5B-1920-475B-B745-DB295BC4862BQ30248286-6B9C2075-0B96-472D-A71F-692C7F71CF2EQ30278586-861097E6-79B9-484F-908C-6C0E72E34276Q30373239-F3539E07-22F9-44CC-8449-7E2E7275D139Q30405402-2652B74C-9C55-4F23-AEC4-5D8328CD9C14Q30839904-884A8B83-5F6B-49A5-98F6-A2DF42724FAFQ31152445-E80C0E6F-1356-4AD7-8C29-F95DD974C5A2Q33618542-C8948D06-B666-48DF-8341-52117F39FC56Q33623429-5641410B-64B9-4560-8C90-A3AEBEC52AE1Q33649200-0EDC306D-E9A1-4D5E-8CB2-00CE67E51A8BQ33750864-042A62B2-2D57-4987-B006-0D76F3F958FBQ33828245-479EBBED-46B9-4BA4-BD83-7C921C4F14B4Q33850487-1AEE7F70-D1C7-423C-93B3-DFAB121AEE24Q33853259-A0BCB8F9-C29C-4532-8340-1EE9E82D1B9AQ33880418-3E30C61E-B068-456F-9CD8-AEBE48437A50Q33899641-9499C167-BA2F-40A0-83A1-2EFD3203000FQ33912595-03700956-5072-464C-B048-7C9CA7656A56Q33934080-0F3D85F4-C8A2-4C46-80CF-BB1229381310Q34057868-678640EB-3EB0-4ED9-8E4A-3711F2D08A16Q34202331-C6C005CA-C6EE-4B46-8EDD-563E7E962EE7Q34243120-8C61F61A-B669-4AD9-ADA2-BBA5DA572F94Q34342183-2C9BB091-7C19-4883-AC2B-265CC29401C8Q34342368-3B35644A-DB1C-42F1-8D7F-F4ED4820228BQ34422128-7C99AC86-43AB-4A1A-87D7-825623FF85F5Q34494208-98F3BC07-7995-49F6-BEA7-FE804420C8C9Q34553819-6DE17E5A-D9E2-4B98-9C73-CF7316A9AC26Q34732822-CB69805F-3215-44D3-B7DC-FC865D658184Q34759994-594F7002-350E-4C25-ACE9-EEA7353010C3Q34784783-F3927940-BDAE-4CD3-B2A4-E173BFF079B8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Arterial inflammation in patients with HIV.
@en
Arterial inflammation in patients with HIV.
@nl
type
label
Arterial inflammation in patients with HIV.
@en
Arterial inflammation in patients with HIV.
@nl
prefLabel
Arterial inflammation in patients with HIV.
@en
Arterial inflammation in patients with HIV.
@nl
P2093
P2860
P921
P356
P1476
Arterial inflammation in patients with HIV.
@en
P2093
Ahmed Tawakol
Amr Abdelbaky
Erin Corsini
Jayanthi Vijayakumar
Jeffrey Wei
Kenneth C Williams
Markella V Zanni
Sharath Subramanian
Steven K Grinspoon
P2860
P304
P356
10.1001/JAMA.2012.6698
P407
P577
2012-07-01T00:00:00Z